120 Results for "

CDK2 activity

" in MedChemExpress (MCE) Product Catalog:
Products (120)

120 Results for "CDK2 activity" in MCE Product Catalog:

Cat. No.: HY-150573
CAS No.: 2410402-88-7
Target:  

CDK Carbonic Anhydrase

Research Areas:  

Cancer

CDK2-IN-12 (compound 10b) is a potent CDK2 inhibitor, with an IC50 of 11.6 μM. CDK2-IN-12 inhibits hCA (carbonic anhydrase) isoforms I, II, IX and XII, with KI values of 3534, 638.4, 44.3, and 48.8 nM. CDK2-IN-12 shows anticancer activity .
loading...
    loading...
Cat. No.: HY-173224
Target:  

CDK Pim

Research Areas:  

Cancer

CDK2/PIM1-IN-1 is an inhibitor of CDK2 (IC50: 0.27 μM) and PIM1 (IC50: 0.67 μM) kinases. CDK2/PIM1-IN-1 induces apoptosis and reduces tumor-promoting TNF-α expression. CDK2/PIM1-IN-1 has antitumor activity .
loading...
    loading...
Cat. No.: HY-173310
CAS No.: 3051587-93-7
Target:  

CDK

Research Areas:  

Cancer

CDK2-IN-44 (Compound 46) is an inhibitor of cyclin-dependent kinase 2 (CDK2). CDK2-IN-44 can effectively inhibit the proliferation of cancer cells and exert its activity in inhibiting cancer cell growth by arresting the cell cycle, promoting Apoptosis, and inducing cellular senescence. CDK2-IN-44 holds promise for use in the research of ovarian cancer and breast cancer .
loading...
    loading...
Cat. No.: HY-172153
Research Areas:  

Cancer

CDK2-IN-41 (Compound 7a) is a CDK2 inhibitor that exerts anticancer activity by binding to CDK2, thereby inhibiting the cell cycle, inducing cytotoxicity, promoting ROS production, and triggering Apoptosis. CDK2-IN-41 exhibits an IC50 of 10 µM against acute myeloid leukemia (AML) HL-60 cells. It holds potential for research in AML-related cancer therapy .
loading...
    loading...
Cat. No.: HY-143497
CAS No.: 2418559-01-8
Target:  

HDAC CDK Apoptosis

Research Areas:  

Cancer

HDAC1/2 and CDK2-IN-1 (compound 14d) is a potent HDAC1, HDAC2 and CDK2 dual inhibitor, with IC50 values of 70.7, 23.1 and 0.80 μM, respectively. HDAC1/2 and CDK2-IN-1 can block the cell cycle and induce apoptosis. HDAC1/2 and CDK2-IN-1 exhibits desirable in vivo antitumor activity .
loading...
    loading...
Cat. No.: HY-168845
CAS No.: 2222285-23-4
Target:  

CDK Apoptosis

Research Areas:  

Cancer

CDK2/9-IN-1 (compound 20a) is an orally active dual inhibitor of CDK2 and CDK9 with IC50 values are 0.004 μM and 0.009 μM respectively. CDK2/9-IN-1 induces apoptosis by regulating G2/M cell cycle arrest. CDK2/9-IN-1 has antitumor activity .
loading...
    loading...
Cat. No.: HY-173147
Target:  

CDK

Research Areas:  

Cancer

CDK2-IN-42 (Compound H63) is a CDK12 inhibitor with an IC50 value of 10 nM. CDK2-IN-42 has anti-ESCC (Esophageal Squamous Cell Carcinoma) cell activity. It can block transcriptional elongation, downregulate the core genes in the G1 phase to induce cell cycle arrest, and alter the CDK12-ATM/ATR-CHEK1/CHEK2 signaling axis, resulting in DNA damage. CDK2-IN-42 can effectively inhibit tumor growth in a xenograft mouse model of human ESCC KYSE150. CDK2-IN-42 holds great promise for research in the field of cancer .
loading...
    loading...
Cat. No.: HY-162683A
CAS No.: 437982-90-6
Target:  

CDK Drug Isomer

Research Areas:  

Cancer

(R)-PHA533533 is an inactive enantiomer (S)-PHA533533 (active enantiomer) (HY-162683). (S)-PHA533533 is a CDK2 inhibitor with antitumor activity .
loading...
    loading...
Cat. No.: HY-115943
CAS No.: 2907774-88-1
Target:  

CDK

Research Areas:  

Cancer

Anticancer agent 30 (compound 6f-Z), a 3-arylidene-2-oxindole derivative, is a selective CDK2 inhibitor with potent anticancer activity .
loading...
    loading...
Cat. No.: HY-170507
CAS No.: 3103862-82-1
Target:  

CDK

Research Areas:  

Cancer

CDK-IN-16 (Compound 5g) is a CDK2/cyclin A2 inhibitor with an IC50 of 1.67 μM. CDK-IN-16 exhibits anticancer activity. The IC50 of CDK-IN-16 against the AGS cell line is 3.5 μM .
loading...
    loading...
Cat. No.: HY-W844558
CAS No.: 721964-51-8
Protein kinase inhibitor 11 (Compound I-96) is a protein kinase inhibitor that can inhibit the activity of PIM-1, CDK-2, GSK-3, and SRC. Protein kinase inhibitor 11 holds promise for research in cancer, immune disorders, and neurodegenerative diseases .
loading...
    loading...
Cat. No.: HY-132914
CAS No.: 2762181-73-5
Target:  

CDK

Research Areas:  

Cancer

CDK/HDAC-IN-1 shows remarkable CDK2/4/6 and HDAC6 inhibitory activity of IC50 = 60.9 ± 2.9, 276 ± 22.3, 27.2 ± 4.2, and 128.6 ± 0.4 nM, respectively.
loading...
    loading...
Cat. No.: HY-118310
CAS No.: 685901-63-7
Target:  

CDK

Research Areas:  

Cancer

Xylocydine is an inhibitor of CDK1/2, inhibiting CDK function in various apoptotic processes. Xylocydine specifically blocks CDK1 and CDK2 activity with IC50 of 1.4 nM and 61 nM, respectively. In addition, Xylocydine downregulates phosphorylated nucleolin and retinoblastoma protein levels. .
loading...
    loading...
Cat. No.: HY-15570
Target:  

CDK

Research Areas:  

Cancer

NU6301 is a NU6102 (a CDK2 inhibitor) (HY-15569) prodrug. NU6301 can rapidly generate NU6102 in mouse plasma. NU6301 has anticancer activity against endometrial cancer .
loading...
    loading...
Cat. No.: HY-168067
Target:  

CDK Caspase Apoptosis

Research Areas:  

Cancer

CDK-IN-14 (B34) is a CDK2 inhibitor (IC50=0.097 μM) with anti-hepatocellular carcinoma activity. CDK-IN-14 blocks the cell cycle of HepG-2 cancer cells through a caspase-mediated mechanism and induces apoptosis .
loading...
    loading...
Cat. No.: HY-163566
Target:  

Apoptosis

Research Areas:  

Cancer

Apoptosis inducer 18, a potent inducer of apoptosis, shows significant cytotoxicity to the breast cancer cell line MCF-7 (IC50=0.559 μM). Apoptosis inducer 18 inhibits cell cycle progression and promotes apoptosis by binding to DNA and causing damage, and by binding to the active site of CDK-2, interfering with its kinase activity. Apoptosis inducer 18 can be used in anti-breast cancer research .
loading...
    loading...
Cat. No.: HY-178168
Target:  

AMPK CDK

Research Areas:  

Neurological Disease

ARUK2010694 (Compound 20) is a potent and selective NUAK1 inhibitor with a pIC50 of 8.7. ARUK2010694 also inhibits CDK2, CDK4 and CDK6 activity, with inhibitory rate of 13%, 63% and 32% at 1 μM. ARUK2010694 can be used for the research of neurological disease, such as Alzheimer’s disease (AD) .
loading...
    loading...
Cat. No.: HY-E70676
Target:  

CDK

Research Areas:  

Cancer

CDK20 is a major controller of cell cycle checkpoints, which regulate cell growth and proliferation and perform a role in the development of many malignancies. CDK20 is thought to have Cyclin-dependent activating kinase (CAK) activity for CDK2 when it is complexed with Cyclin H. CDK20/CycT1 Recombinant Human Active Protein Kinase is an ortholog of CDK20 .
loading...
    loading...
Cat. No.: HY-10012R
CAS No.: 602306-29-6
Target:  

Reference Standards CDK

Research Areas:  

Cancer

AZD-5438 (Standard) is the analytical standard of AZD-5438. This product is intended for research and analytical applications. AZD-5438 is a potent CDK1, CDK2, and CDK9 inhibitor, with IC50s of 16 nM, 6 nM, and 20 nM in cell-free assays, respectively. AZD-5438 shows less inhibition activity against GSK3β, CDK5 and CDK6 .
loading...
    loading...
Cat. No.: HY-136841
CAS No.: 22242-91-7
Target:  

CDK

Research Areas:  

Cancer

SLM6 is a sangivamycin-like molecule. SLM6 is a CDK9 inhibitor. SLM6 inhibits CDK9/cyclin K and CDK9/cyclin T1 kinase activity with IC50s of 280 nM and 133 nM, respectively. SLM6 also inhibits CDK1/cyclin B and CDK2/ cyclin A with IC50s of less than 300 nM. SLM6 induces apoptosis in multiple myeloma (MM) cells .
loading...
    loading...